BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24171220)

  • 1. PSA home tests: ban in France is welcome.
    Prescrire Int; 2013 Sep; 22(141):218. PubMed ID: 24171220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Present status of serum total PSA assay and factors responsible for the inter-kit deviations].
    Kano S
    Nihon Rinsho; 2000 Jul; 58 Suppl():112-7. PubMed ID: 11022696
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum level of prostatic specific antigen in 100 patients with prostatic biopsy].
    Arista-Nasr J; Figueroa-Granados V; Caballero-Mendoza E; Schneider O; López-Carrasco G; Kanan-Falcón M
    Rev Invest Clin; 1998; 50(6):487-90. PubMed ID: 10070220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The present status and future directions for standardization of PSA assays in PSA gray zone].
    Kurokawa K; Yamanaka H; Ishibashi M; Kano S; Arai Y
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():117-22. PubMed ID: 12599556
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparison of Tandem-R PSA and Markit-M PA in the diagnosis of prostate cancer].
    Okegawa T; Kato M; Miyata A; Murata A; Miura I; Yoneda T; Nutahara K; Higashihara E
    Hinyokika Kiyo; 1999 Mar; 45(3):175-8. PubMed ID: 10331169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSA standardization; the past progress and some problems in the future].
    Kano S
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():238-49. PubMed ID: 22207979
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].
    Imai K; Yamanaka H; Kubota Y; Miki M; Ito T; Akaza H; Uchida K; Egawa S; Kuriyama M; Watanabe H; Okihara K; Kotake T; Usami M; Arai Y; Maeda H; Sagiyama K; Saito Y; Sakai H; Shida K
    Hinyokika Kiyo; 1998 Oct; 44(10):755-63. PubMed ID: 9850846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
    Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
    Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.
    Gray MA; Cooke RR; Weinstein P; Nacey JN
    Ann Clin Biochem; 2004 May; 41(Pt 3):207-12. PubMed ID: 15117434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED; Abrahamsson PA
    Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate cancer: update on screening].
    Grosclaude P
    Bull Acad Natl Med; 2008 May; 192(5):1013-8; discussion 1019. PubMed ID: 19238790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
    Tanaka M; Murakami S; Igarashi T; Abe T; Suzuki K; Sekita N; Shimazaki J
    Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of free type and complex type prostate-specific antigen (PSA): differences in immunorecognition by Delfia PSA, ACS-PSA and Eiken PA kits].
    Sumi S; Umeda H; Koga F; Yano M; Imai T; Hosoya Y; Honda M; Maeda S; Suzuki T; Yoshida K; Negishi T
    Hinyokika Kiyo; 1996 Apr; 42(4):279-84. PubMed ID: 8693960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The variation of percent free prostate-specific antigen determined by two different assays.
    Yang CR; Ou YC; Horng YY; Lee HS
    Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer].
    Akino H; Suzuki Y; Okada K
    Nihon Rinsho; 1998 Aug; 56(8):2003-5. PubMed ID: 9750496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
    Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
    Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
    Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
    BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of TANDEM PSA in Japanese cases and comparison with other methods].
    Kuriyama M; Yamamoto N; Shinoda I; Kawada Y; Akimoto S; Shimazaki J
    Hinyokika Kiyo; 1995 Jan; 41(1):39-46. PubMed ID: 7534972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.